2021

Promising treatment for retinal inflammation studied with the Phoenix MICRON™ OCT and exclusive analysis software Insight 2D

In their paper, “Connexin43 Mimetic Peptide Improves Retinal Function and Reduces Inflammation in a Light-Damaged Albino Rat Model,” Guo et al promoted neuroretinal survival in a light damage paradigm by blocking the Connexin43 hemichannels. Using the Phoenix MICRON OCT to examine the structure of the retina at precise retinal locations as shown by the bright

2021

Therapeutic target for retinal degeneration studied with the Phoenix MICRON™ retinal structure and function tools

In their article, “Effect of MMP-9 gene knockout on retinal vascular form and function,” George et al study the effect of knocking out a matrix protein in a mouse model of retinitis pigmentosa using the Phoenix MICRON™ platform including OCT, and Ganzfeld ERG. The combination of the Phoenix MICRON fundus images, OCT revealing the layers,

2021

A better mouse model of retinal vein occlusion with the Phoenix MICRON™ laser and OCT

Retinal vein occlusion is the second most common retinal vascular disorder leading to loss of vision in developed countries (after diabetic retinopathy). A lack of treatment options is partially caused by a lack of effective animal models; most rodent models do not show the essential symptom of cystoid edema and often heal quickly. In their

2021

Stunning fundus images of GFP-positive cells demonstrate new intravitreal injection technique

In their article, “A Novel Method Combining Vitreous Aspiration and Intravitreal AAV2/8 Injection Results in Retina-Wide Transduction in Adult Mice,” Da Costa et al use the Phoenix MICRON™ III imaging platform to take stunning images demonstrating the success of their novel intravitreal injection technique. Gene therapy is a promising treatment option of genetic retinopathies—adeno-associated viruses

2020

The Phoenix MICRON™ IV system and OCT help evaluate promising compounds for treatment of age-related macular degeneration

Age-related macular degeneration affects tens of millions of people worldwide, leading to vision impairment and blindness. Anti-VEGF treatment helps only 25-40% of patients, leaving others with no recourse to this progressive blinding disease. In their article, “Suppression of aberrant choroidal neovascularization through activation of the aryl hydrocarbon receptor,” Choudhary et al explore potential treatment using

2020

Caspase-9 inhibiting eyedrops rescue physiological and functional retinal vein occlusion damage shown with Phoenix MICRON™, OCT, and focal ERG

In a recent well written, compelling article published in Nature Communications, “Endothelial activation of caspase-9 promotes neurovascular injury in retinal vein occlusion,” Avrutsky et al show that caspase-9 inhibition is a promising treatment for retinal vein occlusion. Retinal vein occlusion models hypoxic-ischemic neurovascular damage and is the second leading cause of blindness in working-age adults.

1 2 3